Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium

First scientific presentation of OV-935 (TAK-935) safety and tolerability data in developmental and epileptic encephalopathies from the Phase1b/2a clinical trial Study met primary safety and tolerability endpoints and showed initial evidence of potential efficacy in seizure reduction Data encou...